MetaCap

Arcturus Therapeutics (ARCT) vs Rocket Pharmaceuticals (RCKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcturus Therapeutics (ARCT) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 19.0% versus a loss of 33.4%. Over five years, ARCT leads with a -81.3% price change compared with -91.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($217.7 million vs $214.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARCT+19.01%RCKT-33.45%
+181%+69%-44%
Nov 21, 20251 yearNov 20, 2026
ARCT-79.56%RCKT-93.00%
+35%-32%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARCT versus RCKT key metrics
MetricARCTRCKT
Share price$7.45$1.95
Market cap$214.73M$217.74M
1-day change-1.97%-7.58%
YTD return+21.53%-44.44%
1-year return+19.01%-33.45%
5-year return-81.32%-91.76%
EPS (TTM)$-3.10$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$82.03M$0
Revenue growth (YoY)-46.14%—
Net income (latest FY)$-65.78M$-223.12M
Operating margin-92.96%—
Net margin-80.19%—
52-week high$17.96$5.45
52-week low$5.50$1.94
Distance from 52-week high-58.52%-64.22%
Analyst consensusstrong_buybuy
Avg. price target upside+218.12%+326.15%
Average volume851.45K1.90M
Shares outstanding28.82M111.66M
Employees106202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARCT has outperformed RCKT by 52.5 percentage points over the past year.

About Arcturus Therapeutics

ARCT stock →

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Rocket Pharmaceuticals

RCKT stock →

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees

ARCT vs RCKT FAQ

Which is bigger, Arcturus Therapeutics or Rocket Pharmaceuticals?

Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $217.74M compared with $214.73M for Arcturus Therapeutics (ARCT).

Which stock has performed better over the past year, ARCT or RCKT?

ARCT returned +19.01% over the past 12 months, compared with -33.45% for RCKT (price return, excluding dividends). Past performance does not predict future results.

Are Arcturus Therapeutics and Rocket Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons